检验医学与临床
檢驗醫學與臨床
검험의학여림상
JOURNAL OF LABORATORY MEDICINE AND CLINICAL SCIENCES
2013年
22期
2956-2957,2959
,共3页
肺炎支原体%培养法%被动凝集法%酶联免疫吸附试验
肺炎支原體%培養法%被動凝集法%酶聯免疫吸附試驗
폐염지원체%배양법%피동응집법%매련면역흡부시험
mycoplasma pneumoniae%cultivation%passive agglutination%ELISA
目的:应用并评价肺炎支原体(MP)快速培养法、被动凝集法检测总抗体和酶联免疫吸附试验(ELISA)检测免疫球蛋白M(IgM)抗体在MP感染早期诊断中的价值。方法应用MP快速培养法对该院2009年10月至2010年4月260例急性下呼吸道感染住院惠者的咽拭子标本进行培养,同时用被动凝集法检测患者血清中MP的总抗体和ELISA检测MP的IgM抗体。结果260例急性下呼吸道感染患者咽拭子MP快速签定培养法培养阳性58例,阳性率22.3%。被动凝集法检测总抗体阳性83例,阳性率31.9%。ELISA检测IgM抗体阳性67例,阳性率25.8%。结论MPIgM抗体检测试剂因其方便,快捷,可作为优先检测试验。
目的:應用併評價肺炎支原體(MP)快速培養法、被動凝集法檢測總抗體和酶聯免疫吸附試驗(ELISA)檢測免疫毬蛋白M(IgM)抗體在MP感染早期診斷中的價值。方法應用MP快速培養法對該院2009年10月至2010年4月260例急性下呼吸道感染住院惠者的嚥拭子標本進行培養,同時用被動凝集法檢測患者血清中MP的總抗體和ELISA檢測MP的IgM抗體。結果260例急性下呼吸道感染患者嚥拭子MP快速籤定培養法培養暘性58例,暘性率22.3%。被動凝集法檢測總抗體暘性83例,暘性率31.9%。ELISA檢測IgM抗體暘性67例,暘性率25.8%。結論MPIgM抗體檢測試劑因其方便,快捷,可作為優先檢測試驗。
목적:응용병평개폐염지원체(MP)쾌속배양법、피동응집법검측총항체화매련면역흡부시험(ELISA)검측면역구단백M(IgM)항체재MP감염조기진단중적개치。방법응용MP쾌속배양법대해원2009년10월지2010년4월260례급성하호흡도감염주원혜자적인식자표본진행배양,동시용피동응집법검측환자혈청중MP적총항체화ELISA검측MP적IgM항체。결과260례급성하호흡도감염환자인식자MP쾌속첨정배양법배양양성58례,양성솔22.3%。피동응집법검측총항체양성83례,양성솔31.9%。ELISA검측IgM항체양성67례,양성솔25.8%。결론MPIgM항체검측시제인기방편,쾌첩,가작위우선검측시험。
Objective To apply and evaluate the mycoplasma pneumoniae(MP) rapid culture method and the value of passive agglutination detecting total antibody and IgM antibody test in the early diagnosis of MP infection . Methods MP rapid culture reagent was used in the culture of pharyngeal swab specimens in 260 patients that had a-cute lower respiratory tract infections from Oct .2009 to April .2010 in our hospital .The total antibodies of MP were detected by passive agglutination and IgM antibody was detected by ELISA .Results 58 of 260 cases accepted MP rapid culture method were positive ,and the positive rate was 22 .3% .There were 83 cases with positive result of pas-sive agglutination method ,and the positive rate was 31 .9% .There were 67 cases with positive result of IgM antibod-y ,and the positive rate was 25 .8% .Conclusion The MP IgM antibody test is convenient and fast ,and can be used as a priority testing .